NUTROPIN AQ PEN (somatropin) by Roche. Approved for recombinant human growth hormone [epc]. First approved in 1995.
Drug data last refreshed 18h ago
Recombinant Human Growth Hormone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Worked on NUTROPIN AQ PEN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.